Advertisement

Current Medical Science

, Volume 39, Issue 1, pp 37–43 | Cite as

Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway

  • Yu-pei Zhang
  • Yuan-jun Deng
  • Kai-rui Tang
  • Run-sen Chen
  • Shu Liang
  • Yin-ji Liang
  • Li Han
  • Ling Jin
  • Zi-en Liang
  • Yan-ning Chen
  • Qin-he YangEmail author
Article
  • 30 Downloads

Abstract

This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD). Forty-eight rats were randomly divided into the normal control (NC) group, HFD group or BBR group, with 16 rats in each group. After 8 and 16 weeks of treatment, serum and liver samples were collected. Subsequently, body parameters, biochemical parameters and liver pathology were examined. The expression levels of proteins involved in the SIRT3/AMPK/ACC pathway in the liver were detected by Western blotting. After 8 and 16 weeks of a HFD, the successful establishment of rat models with different degrees of NAFLD was confirmed by hematoxylin and eosin (H&E) and Oil Red O staining. NAFLD rat models exhibited obesity and hyperlipidemia, and the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly decreased compared to those in the NC group. The concurrent administration of BBR with the HFD effectively improved serum and liver lipid profiles and ameliorated liver injury. Furthermore, the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly increased in the BBR group as compared with those in the HFD group. In conclusion, our data suggest that the mechanism by which BBR ameliorates HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.

Key words

berberine non-alcoholic fatty liver disease sirtuin 3 lipid metabolism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rinella ME. Nonalcoholic Fatty Liver Disease. JAMA, 2015,313(22):2263CrossRefGoogle Scholar
  2. 2.
    Argo CK, Caldwell SH. Epidemiology and natural history of non–alcoholic steatohepatitis. Clin Liver Dis, 2009,13(4):511–531CrossRefGoogle Scholar
  3. 3.
    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol, 2013,10(11):686–690CrossRefGoogle Scholar
  4. 4.
    Fan JG, Farrell GC. Epidemiology of non–alcoholic fatty liver disease in China. J Hepatol, 2009,50(1):204–210CrossRefGoogle Scholar
  5. 5.
    Alisi A, Manco M, Panera N, et al. Association between type two diabetes and non–alcoholic fatty liver disease in youth. Ann Hepatol, 2009,8(Suppl 1):S44–S50Google Scholar
  6. 6.
    Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci, 2014,15(5):8713–8742CrossRefGoogle Scholar
  7. 7.
    Osborne B, Bentley NL, Montgomery MK, et al. The role of mitochondrial sirtuins in health and disease. Free Radical Bio Med, 2016,100:164–174CrossRefGoogle Scholar
  8. 8.
    Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty–acid oxidation by reversible enzyme deacetylation. Nature, 2010,464(7285):121–125CrossRefGoogle Scholar
  9. 9.
    Hirschey MD, Shimazu T, Huang JY, et al. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harb Symp Quant Biol, 2011,76:267–277CrossRefGoogle Scholar
  10. 10.
    Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis, 2010,11(1):55–62CrossRefGoogle Scholar
  11. 11.
    Zhang SJ, Li YF, Wang GE, et al. Caffeine ameliorates high energy diet–induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. Food Funct, 2015,6(8):2578–2587CrossRefGoogle Scholar
  12. 12.
    Ge Y, Zhang Y, Li R, et al. Berberine regulated Gck, G6pc, Pck1 and Srebp–1c expression and activated AMPactivated protein kinase in primary rat hepatocytes. Int J Biol Sci, 2011,7(5):673–684CrossRefGoogle Scholar
  13. 13.
    Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP–activated protein kinase with beneficial metabolic effects in diabetic and insulinresistant states. Diabetes, 2006,55(8):2256–2264CrossRefGoogle Scholar
  14. 14.
    Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab, 2008,294(1):E148–E156CrossRefGoogle Scholar
  15. 15.
    Chang X, Yan H, Fei J, et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high–fat diet in rats. J Lipid Res, 2010,51(9):2504–2515CrossRefGoogle Scholar
  16. 16.
    Yan HM, Xia MF, Wang Y, et al. Efficacy of Berberine in Patients with Non–Alcoholic Fatty Liver Disease. PLos One, 2015,10(8):e134172Google Scholar
  17. 17.
    Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013,13(6):637–646CrossRefGoogle Scholar
  18. 18.
    Gomes AP, Duarte FV, Nunes P, et al. Berberine protects against high fat diet–induced dysfunction in muscle mitochondria by inducing SIRT1–dependent mitochondrial biogenesis. Biochim Biophys Acta, 2012,1822(2):185–195CrossRefGoogle Scholar
  19. 19.
    Zhao L, Cang Z, Sun H, et al. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. Bmc Endocr Disord, 2017,17:13CrossRefGoogle Scholar
  20. 20.
    Guo T, Woo SL, Guo X, et al. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet–induced Obesity. Sci Rep, 2016,6:22 612CrossRefGoogle Scholar
  21. 21.
    Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009,296(4):E812–E819CrossRefGoogle Scholar
  22. 22.
    Sanches SC, Ramalho LN, Augusto MJ, et al. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. Biomed Res Int, 2015,2015:574832CrossRefGoogle Scholar
  23. 23.
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010,51(2):679–689CrossRefGoogle Scholar
  24. 24.
    Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science, 2011,332(6037):1519–1523CrossRefGoogle Scholar
  25. 25.
    Vilar–Gomez E, Martinez–Perez Y, Calzadilla–Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015,149(2):367–378, e14–e15CrossRefGoogle Scholar
  26. 26.
    Xie W, Gu D, Li J, et al. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high–fat diet–fed C57BL/6J mice. PLos One, 2011,6(9):e24520CrossRefGoogle Scholar
  27. 27.
    Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis, 2012,32(1):22–29CrossRefGoogle Scholar
  28. 28.
    Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell, 2011,44(2):177–190CrossRefGoogle Scholar
  29. 29.
    Wu T, Liu YH, Fu YC, et al. Direct evidence of sirtuin downregulation in the liver of non–alcoholic fatty liver disease patients. Ann Clin Lab Sci, 2014,44(4):410–418Google Scholar
  30. 30.
    Huang YY, Gusdon AM, Qu S. Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis, 2013,12:171CrossRefGoogle Scholar
  31. 31.
    Kahn BB, Alquier T, Carling D, et al. AMP–activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 2005,1(1):15–25CrossRefGoogle Scholar
  32. 32.
    Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013,13(6):637–646CrossRefGoogle Scholar
  33. 33.
    Shukla S, Sharma A, Pandey VK, et al. Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine–treated HepG2 cells. Toxicol Appl Pharmacol, 2016,291:70–83CrossRefGoogle Scholar
  34. 34.
    Xu M, Xiao Y, Yin J, et al. Berberine promotes glucose consumption independently of AMP–activated protein kinase activation. PLos One, 2014,9(7):e103702CrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology 2018

Authors and Affiliations

  • Yu-pei Zhang
    • 1
  • Yuan-jun Deng
    • 1
  • Kai-rui Tang
    • 1
  • Run-sen Chen
    • 1
  • Shu Liang
    • 1
  • Yin-ji Liang
    • 1
  • Li Han
    • 2
  • Ling Jin
    • 2
  • Zi-en Liang
    • 1
  • Yan-ning Chen
    • 1
  • Qin-he Yang
    • 1
    Email author
  1. 1.School of Traditional Chinese MedicineGuangzhouChina
  2. 2.Department of Traditional Chinese Medicinethe First Affiliated Hospital of Jinan UniversityGuangzhouChina

Personalised recommendations